Yu Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yu Jiang has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
- John S. Witte
Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, USA
4 shared publications - Linda Kachuri
Stanford University
3 shared publications Adaeze A. Emeka
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
2 shared publicationsAlexandre Mamedov
Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, ON, Canada
2 shared publicationsAndrew Loblaw
Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, ON, Canada
2 shared publicationsAnjali Vij
Department of Urologic Surgery, University of California, Davis Medical Center, Sacramento, CA, USA
2 shared publications
Latest Publications
- Open Access
An LLM-assisted framework for accelerated and verifiable clinical hypothesis testing from electronic health records
Acquiring insights from electronic health records (EHRs) is slowed by manual analytical workflows that limit scalability and reproducibility. We present LATCH (LLM-Assisted Testing of Clinical Hypotheses), an agentic framework that converts natural language clinical hypotheses into fully auditable analyses on structured EHR data. LATCH integrates LLM-assisted semantic layers with deterministic execution pipelines to automate cohort construction, statistical analysis, and result reporting, while isolating patient-level data from LLM-involved steps. Using diabetes as a model disease, LATCH reproduced findings from 20 published studies within 3-15 minutes per study. Beyond replication, LATCH enabled study extensions and new insight generation through simple natural language hypothesis modifications. We demonstrated LATCH across 102 hypothesis tests spanning reproduction, extension, and insight generation. We systematically stress-tested LATCH to characterize its limitations and operational boundaries. LATCH provides a scalable framework for reproducible real-world evidence generation, reducing analytical bottlenecks and improving reliability of AI-assisted biomedical discovery while preserving human oversight.
Open AccessAn LLM-assisted framework for accelerated and verifiable clinical hypothesis testing from electronic health records
Acquiring insights from electronic health records (EHRs) is slowed by manual analytical workflows that limit scalability and reproducibility. We present LATCH (LLM-Assisted Testing of Clinical Hypotheses), an agentic framework that converts natural language clinical hypotheses into fully auditable analyses on structured EHR data. LATCH integrates LLM-assisted semantic layers with deterministic execution pipelines to automate cohort construction, statistical analysis, and result reporting, while isolating patient-level data from LLM-involved steps. Using diabetes as a model disease, LATCH reproduced findings from 20 published studies within 3-15 minutes per study. Beyond replication, LATCH enabled study extensions and new insight generation through simple natural language hypothesis modifications. We demonstrated LATCH across 102 hypothesis tests spanning reproduction, extension, and insight generation. We systematically stress-tested LATCH to characterize its limitations and operational boundaries. LATCH provides a scalable framework for reproducible real-world evidence generation, reducing analytical bottlenecks and improving reliability of AI-assisted biomedical discovery while preserving human oversight.
- Open Access
- 10 February 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (2) , 334-344
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups
We conducted a multiancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry, 58,236 African ancestry, 23,546 Hispanic/Latino and 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (P ≤ 5 × 10−8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n = 95,768). Meta-analyzing discovery and replication (n = 392,522) identified 447 variants, of which a further 111 were novel. Out-of-sample variance in PSA explained by our genome-wide polygenic risk scores ranged from 11.6% to 16.6% for European ancestry, 5.5% to 9.5% for African ancestry, 13.5% to 18.2% for Hispanic/Latino and 8.6% to 15.3% for Asian ancestry and decreased with increasing age. Midlife genetically adjusted PSA levels were more strongly associated with overall and aggressive prostate cancer than unadjusted PSA levels. Our study highlights how including proportionally more participants from underrepresented populations improves genetic prediction of PSA levels, offering potential to personalize prostate cancer screening.
- 10 February 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (2) , 334-344
Open AccessGenome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups
We conducted a multiancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry, 58,236 African ancestry, 23,546 Hispanic/Latino and 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (P ≤ 5 × 10−8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n = 95,768). Meta-analyzing discovery and replication (n = 392,522) identified 447 variants, of which a further 111 were novel. Out-of-sample variance in PSA explained by our genome-wide polygenic risk scores ranged from 11.6% to 16.6% for European ancestry, 5.5% to 9.5% for African ancestry, 13.5% to 18.2% for Hispanic/Latino and 8.6% to 15.3% for Asian ancestry and decreased with increasing age. Midlife genetically adjusted PSA levels were more strongly associated with overall and aggressive prostate cancer than unadjusted PSA levels. Our study highlights how including proportionally more participants from underrepresented populations improves genetic prediction of PSA levels, offering potential to personalize prostate cancer screening.
- Open Access
Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis
Over the last two decades, tumor necrosis factor-alpha inhibitors (TNF-Is) have become standard therapies for chronic inflammatory disorders, with an ongoing expansion of indications and off-label applications
Open AccessTumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis
Over the last two decades, tumor necrosis factor-alpha inhibitors (TNF-Is) have become standard therapies for chronic inflammatory disorders, with an ongoing expansion of indications and off-label applications
- 5 October 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 269, 457-465
Outer Retinal Thinning is Associated With Brain Atrophy in Early Age-Related Macular Degeneration
- 5 October 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 269, 457-465
Outer Retinal Thinning is Associated With Brain Atrophy in Early Age-Related Macular Degeneration
- Open Access
- 19 November 2021
- Published by Elsevier in Human Genetics and Genomics Advances
- Vol. 3 (1)
Genetic factors associated with prostate cancer conversion from active surveillance to treatment
- 19 November 2021
- Published by Elsevier in Human Genetics and Genomics Advances
- Vol. 3 (1)
Open AccessGenetic factors associated with prostate cancer conversion from active surveillance to treatment
- Open Access
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment
Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 6,361 PC patients who initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 single nucleotide polymorphisms (SNPs) associated with conversion, 15 of which were not previously associated with PC risk. We found two genes associated with conversion ( MAST3 , p = 6.9×10 -7 and GAB2 , p = 2.0×10 -6 ). Moreover, increasing values of a previously validated 269-SNP genetic risk score (GRS) for PC was positively associated with conversion (e.g., comparing the highest to the two middle deciles gave a hazard ratio [HR] = 1.13; 95% Confidence Interval [CI]= 0.94-1.36); whereas, decreasing values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% CI, 1.04-1.50). These results suggest that germline genetics may help inform and individualize the decision of AS—or the intensity of monitoring on AS— versus treatment for the initial management of patients with low-risk PC.
Open AccessGenetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment
Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 6,361 PC patients who initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 single nucleotide polymorphisms (SNPs) associated with conversion, 15 of which were not previously associated with PC risk. We found two genes associated with conversion ( MAST3 , p = 6.9×10 -7 and GAB2 , p = 2.0×10 -6 ). Moreover, increasing values of a previously validated 269-SNP genetic risk score (GRS) for PC was positively associated with conversion (e.g., comparing the highest to the two middle deciles gave a hazard ratio [HR] = 1.13; 95% Confidence Interval [CI]= 0.94-1.36); whereas, decreasing values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% CI, 1.04-1.50). These results suggest that germline genetics may help inform and individualize the decision of AS—or the intensity of monitoring on AS— versus treatment for the initial management of patients with low-risk PC.